The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma

Internal Medicine

Volumn 49, Issue 10, 2010, Pages 887-895

  Okamoto, Kinya ^a   Ishida, Chihiro ^a   Ikebuchi, Yuichiro ^a   Mandai, Mari ^a   Mimura, Kenichi ^a   Murawaki, Yoshikazu ^a   Yuasa, Isao ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Gene polymorphism; Hepatitis virus C; Hepatocellular carcinoma; Interleukin 1 beta; MMP 3; Prognosis

Indexed keywords

ADENINE; CYTOSINE; GELATINASE B; GUANINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; STROMELYSIN; THYMINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C VIRUS; HETEROZYGOTE; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK FACTOR; VARIABLE NUMBER OF TANDEM REPEAT;

AGED; ALLELES; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTERLEUKIN-1BETA; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS;

EID: 77952947233     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3268     Document Type: Article

References (49)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16, 2004.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
3. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 37: 493-503, 2003.
4. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25: 387-408, 2006.
5. Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall LA. Manipulation of distinct NF kappaB proteins alters interleukin-1 beta-induced human rheumatoid synovial fibroblast prostaglandin E2 formation. J Biol Chem 271: 31496-31501,1996.
6. El-Omer EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404: 398-402, 2000.
7. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1 b production in vitro. Scand J Immunol 47: 195-198, 1998.
8. Hwang IR, Kodama T, Kikuchi S, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1 beta production in Helicobacter pylori infection. Gastroenterology 123: 1793-1803,2002.
9. Tanaka Y, Furuta T, Suzuki S, et al. Impact of interleukin-1 beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. J Infect Dis 187: 1822-1825,2003.
10. Hirankarn N, Kimkong I, Kummee P, Tangkijvanich P, Poovorawan Y. Interleukin-1 beta gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J Gastroenterol 12: 776-779, 2006.
11. Migita K, Maeda Y, Abiru S, et al. Polymorphisms of interleukin-1 beta in Japanese patients with hepatitis B virus infection. J Hepatol 46: 381-386, 2007.
12. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 115: 209-218,2005.
13. Murawaki Y, Nishimura Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Plasma transforming growth factor-beta 1 concentration in patients with chronic viral hepatitis. J Gastroenterol Hepatol 13: 680-684, 1998.
14. Gewaltig J, Mngasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of transforming growth factor-b1 gene with the rate of progression of HCV-induced liver fibrosis. Cln Chim Acta 316: 83-94, 2002.
15. Kim YJ, Lee HS, Im JP, et al. Association of transforming growth factor-beta1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp Mol Med 35: 196-202, 2003.
16. Falleti E, Fabris C, Toniutto P, et al. TGF-beta 1 genotypes in cirrhosis: relationship with the occurrence of liver cancer. Cytokine 44: 256-261, 2008.
17. Suzuki S, Tanaka Y, Orito E, et al. Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 18: 1139-1143, 2003.
18. Forget MA, Desrosiers MM, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 77: 465-480, 1999.
19. Yamamoto H, Itoh F, Adachi Y, et al. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology 112: 1290-1296, 1997.
20. Okazaki I, Wada N, Nakano M, et al. Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas. Hepatology 25: 580-584, 1997.
21. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 73: 209-215, 1995.
22. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58: 5321-5325,1998.
23. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99: 1788-1794, 1999.
24. Ghilardi G, Biondi ML, Mangoni J, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 7:2344-2346,2001.
25. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 271: 13055-13060, 1996.
26. Ghilardi G, Biondi ML, Caputo M, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 8: 3820-3823, 2002.
27. Fang S, Jin X, Wang R, et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 26: 481-486, 2005.
28. Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med 36: 409-414,2007.
29. Dunleavey L, Beyyzade L, Ye S. Rapid genotype analysis of the matrix metalloproteinase-1 gene 1G/2G polymorphism that is associated with risk of cancer. Matrix Biol 19: 175-177, 2000.
30. Gnasso A, Motti C, Irace C, et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 20: 1600-1605,2000.
31. Nelissen I, Vandenbroeck K, Fiten P, et al. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol 105: 58-63, 2000.
32. Wood NAP, Thomson SC, Smith RM, Bidwell JL. Identification of human TGF-b1 signal (leader) sequence polymorphisms by PCR-RFLP. J Immunol Meth 234: 117-122, 2000.
33. Wang Y, Kato N, Hoshida Y, et al. Interleukin-1 gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 37: 65-71, 2003.
34. Migita K, Miyazoe S, Maeda Y, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection--association between TGF-beta 1 polymorphisms and hepatocellular carcinoma. J Hepatol 42: 505-510, 2005.
35. Hinoda Y, Okayama N, Takano N, et al. Association of functional polymorphisms of matrix metalloproteinase (MMP-1) and MMP-3 genes with colorectal cancer. Int J Cancer 102: 526-529, 2002.
36. Song X, Voronov E, Dvorkin T, et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 171: 6448-6456, 2003.
37. Thampatty BP, Li H, Im HJ, Wang JH. EP4 receptor regulates collagen type-I, MMP-1, and MMP-3 gene expression in human ten-don fibroblasts in response to IL-1? treatment. Gene 386: 154-161,2007.
38. Sasaki Y, Imaoka S, Ishiguro S, et al. Clinical features of small hepatocellular carcinomas as assessed by histologic grades. Surgery 119: 252-260, 1996.
39. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001.
40. INK4B is a potential effector of TGF-b-induced cell cycle arrest. Nature 371: 257-261, 1994.
41. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Trans-forming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92: 5545-5549, 1995.
42. Liu P, Menon K, Alvarez E, Lu K, Teicher BA. Transforming growth factor-beta and response to anti-cancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol 16: 599-610,2000.
43. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 6: 1899-1904, 1987.
44. Hettiaratchi A, Hawkins NJ, McKenzie G, et al. The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer 96: 783-792, 2007.
45. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Immunocytochemical detection of MMP-3 and -10 expression in hepatocellular carcinoma. Anticancer Res 20: 4585-4590, 2000.
46. Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL. Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 9: R67, 2007.
47. Sciavolino PJ, Lee TH, Vilcek J. Interferon-beta induces metalloproteinase mRNA expression in human fibroblasts. Role of activator protein-1. J Biol Chem 269: 21627-21634, 1994.
48. Chen J-S, Wang Q, Fu X-H, et al. Involvement of PI3K/PTEN/ AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 39: 177-186, 2009.
49. Variaktaris E, Vassiliou S, Nkenke E, et al. A metalloproteinase-9 polymorphism which affects its expression is associated with in-creased risk for oral squamous cell carcinoma. Eur J Surg Oncol 34: 450-455, 2008.